Spots Global Cancer Trial Database for Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Official Title: Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate

Study ID: NCT01540994

Conditions

Prostatic Neoplasm

Interventions

radiation therapy

Study Description

Brief Summary: The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.

Detailed Description: External beam radiation therapy for prostate cancer, while effective, takes up to 9 weeks to deliver on a Monday through Friday basis. Recent phase I/II studies from Seattle and Palo Alto using stereotactic guidance to deliver high doses of radiation to the prostate over a 1 to 2 week period of time suggest that outcomes may be equal or superior to standard approaches. These data, combined with markedly improved convenience for patients, make radiosurgery (SBRT) for early-stage prostate cancer an enticing option. The goal of this study is to offer a radiosurgical option to patients within the Sharp system under the umbrella of an IRB-approved study.